Updated Jul 16, 2026
SEIDENBERG BETH C has filed 3 SEC Form 4 filings across 3 companies in the last 90 days — selling. Lifetime open-market sales: $720K.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | KYTX | Kyverna Therapeutics, Inc. | A — Grant or award | 5.1K | $0.00 | |
| 2025-05-29 | KYTX | Kyverna Therapeutics, Inc. | A — Grant or award | 16.6K | $0.00 | |
| 2025-05-21 | SLRN | ACELYRIN, Inc. | D — Derivative transaction | 9.79M | — | |
| 2025-05-21 | SLRN | ACELYRIN, Inc. | D — Derivative transaction | 60.0K | — | |
| 2024-10-30 | VERA | Vera Therapeutics, Inc. | S — Open-market sale [10b5-1] | 202 | $49.54 | $10K |
| 2024-10-30 | VERA | Vera Therapeutics, Inc. | S — Open-market sale [10b5-1] | 14.8K | $48.01 | $710K |
SEIDENBERG BETH C is a corporate insider — currently tracked as Director of Sagimet Biosciences Inc. (SGMT). InsiderAlpha tracks every SEC Form 4 filing in real time.
3 primary Form 4 filings in the last 90 days, covering 3 companies.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($720K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live SEIDENBERG BETH C profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.